Our Facilities

Our Facilities

Opened in 1969 this former Sterling Drug facility provides Contract Development and Manufacturing services.

  • The 450 M3 reactor manufacturing capacity available on the site allows for rapid entry for new products to full cGMP (Current Good Manufacturing Practice).

  • The Dudley site produces clinical trial and commercial quantities of API (Active Pharmaceutical Ingredients) product from grams to tonnes per annum.

  • The site is spread over an area of 169,900 sq. metres.

  • The R&D facility on site has 50 scientists, focussed on process development and industrialisation support with extensive hazard evaluation capability.

  • cGMP (Current Good Manufacturing Practice) Pilot Plant.

  • Dudley has three main plant areas which can perform demanding and hazardous chemistry such as hydrogenation, halogenation, Friedel-Crafts and cyanation.

  • The site is approved by MHRA (Medical Health Regulatory Authority), PMDA and FDA approved with the last FDA inspection in 2011.